Formulary
Sucroferric oxyhydroxide: Indications, Dosing, Side Effects and Interactions
Sucroferric oxyhydroxide clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Sucroferric oxyhydroxide: Indications, Dosing, Side Effects and Interactions
Sucroferric oxyhydroxide clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Hyperphosphataemia in patients with chronic kidney disease on haemodialysis or peritoneal dialysis**
- **Adult** (By Mouth): Initially 1.5 g daily in 3 divided doses, dose to be taken with meals, then adjusted in steps of 500 mg every 2-4 weeks, dose adjusted according to serum-phosphate concentration; maintenance 1.5-2 g daily in divided doses; maximum 3 g per day.
Cautions
Gastric disorders; hepatic disorders; major gastrointestinal surgery; peritonitis in the last 3 months
Contraindications
Haemochromatosis; iron accumulation disorders
Side effects
Common or very common Constipation; diarrhoea; gastrointestinal discomfort; gastrointestinal disorders; nausea; product taste abnormal; tooth discolouration; vomiting Uncommon Dysphagia; dyspnoea; electrolyte imbalance; fatigue; headache; skin reactions; tongue discolouration Side-effects, further information Discoloured faeces may mask the visual signs of gastrointestinal bleeding.
Interactions
**Other interactions (4):**
- When administering any medicinal product that is already known to interact with iron (like alendronate and doxycycline) or has the potential to interact with sucroferric oxyhydroxide based only on...
- In vitro studies with the following active substances did not show any relevant interaction: acetylsalicylic acid, cephalexin, cinacalcet, ciprofloxacin, clopidogrel, enalapril, hydrochlorothiazide,...
- They have been conducted in healthy human male and female subjects with losartan, furosemide, digoxin, warfarin, and omeprazole.
- Data from clinical studies have shown that sucroferric oxyhydroxide does not affect the lipid lowering effects of HMG-CoA reductase inhibitors (e.g., atorvastatin and simvastatin).
Pregnancy
Manufacturer advises use only if potential benefit outweighs risk-no information available.
Breast feeding
Manufacturer advises avoid-no information available.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Sucroferric oxyhydroxide in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

